Dudediligence.

Aligos Therapeutics, Inc

ALGSNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$1.3MSep ’24$606,000Dec ’24$311,000Mar ’25$965,000Jun ’25$741,000Sep ’25$169,000Dec ’25$2.8MMar ’26$0.00Jun ’26
Net income, by quarter
−$19.3MSep ’24−$82.2MDec ’24$43.1MMar ’25−$15.9MJun ’25−$31.5MSep ’25−$19.9MDec ’25−$23.0MMar ’26−$1.5MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$0.00$0.00$6.2M$3.6M$2.2M
Operating income−$128.3M−$97.6M−$88.1M−$89.2M−$88.0M
Net income−$128.3M−$96.0M−$87.7M−$131.2M−$24.2M
Operating cash flow−$115.7M−$79.4M−$79.0M−$80.7M−$82.5M
Free cash flow−$116.6M−$80.3M−$79.0M−$80.9Mnone on file
Cash$186.8M$81.3M$135.7M$37.0M$18.3M
Shares outstanding42.7M42.9M3.0M3.9M6.2M